Innoviva, Inc.
INVA
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidiniuā¦ read more
Healthcare
Biotechnology
21 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$20.72
Price-1.15%
-$0.25
1Y
Price
Market Cap
$1.530b
Small
Price/Earnings 3y Avg5y Avg
4.9x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+244.1%
EBITDA Margin+190.4%
Net Profit Margin+35.5%
Free Cash Flow Margin+244.1%
EBITDA Margin+190.4%
Net Profit Margin+35.5%
Free Cash Flow MarginRevenue
$424.122m
-0.2%
1y CAGR+11.3%
3y CAGR+6.9%
5y CAGREarnings
$504.344m
+86.0%
1y CAGR+352.7%
3y CAGR+260.6%
5y CAGREPS
$6.01
+82.1%
1y CAGR+271.7%
3y CAGR+202.0%
5y CAGRBook Value
$1.342b
$1.837b
Assets$494.932m
Liabilities$331.418m
DebtDebt to Assets
18.1%
0.5x
Debt to EBITDAFree Cash Flow
$180.851m
-3.0%
1y CAGR+10.0%
3y CAGR-0.1%
5y CAGRNo items found.
Press Releases
Statements and updates from the company